Trevi Therapeutics Inc (TRVI NASDAQ) stock market data APIs
$18.6605
0.45(2.4%)
as of August 7, 2026
Try our APIs with
free plan!
Trevi Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Prev. Close
18.6605
Open
19.1074
High
19.1311
Low
17.8483
52 wk Range
6.93-20.22
Market Cap
2 637 M
Shares Outstanding
142 M
EPS
-0.11
Beta
1.072
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Trevi Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at €19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
Get Trevi Therapeutics Inc data using free add-ons & libraries
Get Trevi Therapeutics Inc Fundamental Data
Trevi Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -52 629 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
€
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-06
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Trevi Therapeutics Inc News
New
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 In...
Trevi Therapeutics to Participate in Upcoming August Conferences
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbup...
Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market
Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored strong clinical trial results from its treatment candidate for chronic cough...
Tuesday's ETF Movers: IHE, PSI
In trading on Tuesday, the iShares US Pharmaceuticals ETF is outperforming other ETFs, up about 3.1% on the day. Components of that ETF showing particular strength include shares of Crinetics Pharmac...
Get Trevi Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
€19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
€99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
